Intrinsiqs

Is Gyre Therapeutics, Inc. overvalued?

Gyre Therapeutics, Inc. (GYRE) — key valuation metrics and fundamentals.

No verdict
Price
$6.68
Fair value
Current P/E
Normal P/E
Market cap
$744.7M
Dividend yield
377.3%
Return on equity
-15.8%
Sector
Healthcare

See the full interactive analysis →

Fair value compares GYRE's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.